Minocycline as Neuroprotectant After Aneurysmal Subarachnoid Hemorrhage

Subarachnoid Aneurysm Hemorrhage Clinical Trial

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02113176
• Other study ID #: MINO-SAH
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• Start date: January 2010
• Est. completion date: December 2018

Study information

• Verified date: May 2022
• Source: University at Buffalo
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and efficacy of a drug minocycline in improving outcomes at 3 months after rupture of an aneurysm in the head.

Description:

Prior to the drug:

If you decide to take part in this study, you will have a brief interview about your medical history and any medications you are taking. You will have a medical and neurological examination, CT scan and/or an angiogram to look at the blood vessel and blood supply going to the brain, and blood samples drawn for a complete blood count, chemistry analysis and cardiac enzymes (to assess any recent damage to your heart). You will have a surgery or an image guided procedure to close your aneurysm.

Additionally, during the course of the study you may be asked to have a computerized tomography (CT scan) or magnetic resonance imaging (MRI) if there is a necessity. These tests will reveal areas that might have been damaged in your brain.

Drug:

If the tests show that you qualify as a candidate for this study, you will be randomly assigned (like a flip of a coin) to have either the minocycline drug or a dummy drug that looks the same but does not have the drug in it. For the first 7 days, the drug will be given as an injection two times a day and after that for 14 days once a day by mouth. Rest of the care will be standard like in any aneurysm patient. We study the status of your blood vessel surrounding the brain with ultrasound daily to see if they have any narrowing. If the doctors find any narrowing, you will be treated to relive the narrowing. If you are discharged home at any point in the 21 days, you will be switch the oral drug and given the required drugs with instructions.

Follow up:

Before you are discharged from the hospital and at 7, 21, 30 and 90 days after the start of the drug, the following evaluations will be performed: a complete physical and neurological examinations.

As part of this study, you are required to return to the hospital or to your physician at one (1), seven (7), twenty-one (21), thirty (30), ninety (90) days after stroke onset. You will have a physical exam, a complete neurological exam. Additionally, you will be asked questions about any health problems or hospitalizations you have had since you were discharged from the hospital.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2018
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• = 18 yrs of age

• Ruptured aneurysm

• Initiate treatment within 72 hours of SAH

• Pre Rankin = 1

Exclusion Criteria:

• Hunt & Hess 5 with no improvement

• ICP > 30

• No plans to treat aneurysm

• Allergy to Tetracycline / Antibiotics

• Creatinine >2

• Platelets < 75,000

• Other brain diseases

• Previous infection requiring Tetracycline

Related Conditions & MeSH terms

• Aneurysm
• Hemorrhage
• Subarachnoid Aneurysm Hemorrhage

Intervention

Drug:
• Minocycline

Locations

Country	Name	City	State
United States	University of Buffalo Neurosurgery	Buffalo	New York

Sponsors (2)

Lead Sponsor	Collaborator
University at Buffalo	University at Buffalo Neurosurgery

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	adverse event	The primary objective of the study is to evaluate the effectiveness of minocycline in improving outcomes for patients after aneurysmal SAH.; To determine the safety of minocycline 200mg/day for 21 days in the treatment arm after aneurysmal subarachnoid hemorrhage.	21 days
Secondary	comparative stroke scale	To demonstrate a significant difference in outcome at 3 months as measured by NIHSS, mRS, BI and GOS in the minocycline treatment group when compared to the placebo arm.; To determine any significant differences in vasospasm rates, duration of vasospasm, interventions for vasospasm, vasospasm related infarcts and delayed ischemic deficits between minocycline and placebo arms	3 months